In the past week, BIIB stock has gone up by 2.70%, with a monthly gain of 0.93% and a quarterly plunge of -9.79%. The volatility ratio for the week is 3.13%, and the volatility levels for the last 30 days are 2.97% for Biogen Inc The simple moving average for the last 20 days is 0.69% for BIIB stock, with a simple moving average of -25.19% for the last 200 days.
Is It Worth Investing in Biogen Inc (NASDAQ: BIIB) Right Now?
Biogen Inc (NASDAQ: BIIB) has a price-to-earnings ratio that is above its average at 11.89x. The stock has a 36-month beta value of 0.12. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 4 as “overweight,” 20 as “hold,” and 0 as “sell.”
The public float for BIIB is 145.78M, and at present, short sellers hold a 2.18% of that float. On May 15, 2025, the average trading volume of BIIB was 1.75M shares.
BIIB) stock’s latest price update
Biogen Inc (NASDAQ: BIIB)’s stock price has plunge by -2.27relation to previous closing price of 123.16. Nevertheless, the company has seen a 2.70% surge in its stock price over the last five trading sessions. schaeffersresearch.com reported 2025-05-14 that Last week, I took a closer look at outside days on a candlestick chart of the S&P 500 Index (SPX).
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with HSBC Securities repeating the rating for BIIB by listing it as a “Hold.” The predicted price for BIIB in the upcoming period, according to HSBC Securities is $118 based on the research report published on April 28, 2025 of the current year 2025.
Bernstein gave a rating of “Mkt Perform” to BIIB, setting the target price at $160 in the report published on February 11th of the current year.
BIIB Trading at -6.42% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.42% of loss for the given period.
Volatility was left at 2.97%, however, over the last 30 days, the volatility rate increased by 3.13%, as shares surge +2.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.62% lower at present.
During the last 5 trading sessions, BIIB rose by +2.70%, which changed the moving average for the period of 200-days by -43.00% in comparison to the 20-day moving average, which settled at $119.55. In addition, Biogen Inc saw -21.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from DORSA CAROLINE, who purchase 1,235 shares at the price of $122.72 back on May 02 ’25. After this action, DORSA CAROLINE now owns 27,842 shares of Biogen Inc, valued at $151,559 using the latest closing price.
SHERWIN STEPHEN A, the Director of Biogen Inc, sale 8,760 shares at $150.02 during a trade that took place back on Mar 07 ’25, which means that SHERWIN STEPHEN A is holding 11,318 shares at $1,314,142 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.8 for the gross margin
The net margin for Biogen Inc stands at 0.15. The total capital return value is set at 0.13. Equity return is now at value 9.19, with 5.42 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 0.39. The interest coverage ratio of the stock is 24.91.
When we switch over and look at the enterprise to sales, we see a ratio of 2.23. The receivables turnover for the company is 6.05for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.44.
Conclusion
To sum up, Biogen Inc (BIIB) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
